387 related articles for article (PubMed ID: 22260662)
1. Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis.
Gotoh M; Fujiwara Y; Yue J; Liu J; Lee S; Fells J; Uchiyama A; Murakami-Murofushi K; Kennel S; Wall J; Patil R; Gupte R; Balazs L; Miller DD; Tigyi GJ
Biochem Soc Trans; 2012 Feb; 40(1):31-6. PubMed ID: 22260662
[TBL] [Abstract][Full Text] [Related]
2. Autotaxin and LPA receptor signaling in cancer.
Houben AJ; Moolenaar WH
Cancer Metastasis Rev; 2011 Dec; 30(3-4):557-65. PubMed ID: 22002750
[TBL] [Abstract][Full Text] [Related]
3. Regulation of tumor cell - Microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis.
Tigyi GJ; Yue J; Norman DD; Szabo E; Balogh A; Balazs L; Zhao G; Lee SC
Adv Biol Regul; 2019 Jan; 71():183-193. PubMed ID: 30243984
[TBL] [Abstract][Full Text] [Related]
4. The autotaxin-lysophosphatidic acid-lysophosphatidic acid receptor cascade: proposal of a novel potential therapeutic target for treating glioblastoma multiforme.
Tabuchi S
Lipids Health Dis; 2015 Jun; 14():56. PubMed ID: 26084470
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of autotaxin/lysophospholipase d inhibitors.
Federico L; Pamuklar Z; Smyth SS; Morris AJ
Curr Drug Targets; 2008 Aug; 9(8):698-708. PubMed ID: 18691016
[TBL] [Abstract][Full Text] [Related]
6. The autotaxin-lysophosphatidic acid pathway in pathogenesis of rheumatoid arthritis.
Orosa B; García S; Conde C
Eur J Pharmacol; 2015 Oct; 765():228-33. PubMed ID: 26297977
[TBL] [Abstract][Full Text] [Related]
7. Biological roles of lysophosphatidic acid signaling through its production by autotaxin.
Okudaira S; Yukiura H; Aoki J
Biochimie; 2010 Jun; 92(6):698-706. PubMed ID: 20417246
[TBL] [Abstract][Full Text] [Related]
8. Autotaxin-LPA axis regulates hMSC migration by adherent junction disruption and cytoskeletal rearrangement via LPAR1/3-dependent PKC/GSK3β/β-catenin and PKC/Rho GTPase pathways.
Ryu JM; Han HJ
Stem Cells; 2015 Mar; 33(3):819-32. PubMed ID: 25376707
[TBL] [Abstract][Full Text] [Related]
9. Autotaxin regulates vascular development via multiple lysophosphatidic acid (LPA) receptors in zebrafish.
Yukiura H; Hama K; Nakanaga K; Tanaka M; Asaoka Y; Okudaira S; Arima N; Inoue A; Hashimoto T; Arai H; Kawahara A; Nishina H; Aoki J
J Biol Chem; 2011 Dec; 286(51):43972-43983. PubMed ID: 21971049
[TBL] [Abstract][Full Text] [Related]
10. alpha- and beta-substituted phosphonate analogs of LPA as autotaxin inhibitors.
Cui P; McCalmont WF; Tomsig JL; Lynch KR; Macdonald TL
Bioorg Med Chem; 2008 Mar; 16(5):2212-25. PubMed ID: 18082408
[TBL] [Abstract][Full Text] [Related]
11. Autotaxin/Lysophosphatidic Acid Axis: From Bone Biology to Bone Disorders.
Alioli C; Demesmay L; Peyruchaud O; Machuca-Gayet I
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408784
[TBL] [Abstract][Full Text] [Related]
12. Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis.
Li S; Wang B; Xu Y; Zhang J
Mol Cancer; 2011 Feb; 10():18. PubMed ID: 21314984
[TBL] [Abstract][Full Text] [Related]
13. Production of extracellular lysophosphatidic acid in the regulation of adipocyte functions and liver fibrosis.
Yang F; Chen GX
World J Gastroenterol; 2018 Sep; 24(36):4132-4151. PubMed ID: 30271079
[TBL] [Abstract][Full Text] [Related]
14. ATX-LPA receptor axis in inflammation and cancer.
Liu S; Murph M; Panupinthu N; Mills GB
Cell Cycle; 2009 Nov; 8(22):3695-701. PubMed ID: 19855166
[TBL] [Abstract][Full Text] [Related]
15. New insights into the autotaxin/LPA axis in cancer development and metastasis.
Leblanc R; Peyruchaud O
Exp Cell Res; 2015 May; 333(2):183-189. PubMed ID: 25460336
[TBL] [Abstract][Full Text] [Related]
16. The role and therapeutic potential of the autotaxin-lysophosphatidate signalling axis in breast cancer.
Teo K; Brunton VG
Biochem J; 2014 Oct; 463(1):157-65. PubMed ID: 25195735
[TBL] [Abstract][Full Text] [Related]
17. Discovery of potent inhibitors of the lysophospholipase autotaxin.
Shah P; Cheasty A; Foxton C; Raynham T; Farooq M; Gutierrez IF; Lejeune A; Pritchard M; Turnbull A; Pang L; Owen P; Boyd S; Stowell A; Jordan A; Hamilton NM; Hitchin JR; Stockley M; MacDonald E; Quesada MJ; Trivier E; Skeete J; Ovaa H; Moolenaar WH; Ryder H
Bioorg Med Chem Lett; 2016 Nov; 26(22):5403-5410. PubMed ID: 27780639
[TBL] [Abstract][Full Text] [Related]
18. Targeting the autotaxin - Lysophosphatidic acid receptor axis in cardiovascular diseases.
Zhao Y; Hasse S; Zhao C; Bourgoin SG
Biochem Pharmacol; 2019 Jun; 164():74-81. PubMed ID: 30928673
[TBL] [Abstract][Full Text] [Related]
19. Autotaxin inhibitors: a patent review (2012-2016).
Nikolaou A; Kokotou MG; Limnios D; Psarra A; Kokotos G
Expert Opin Ther Pat; 2017 Jul; 27(7):815-829. PubMed ID: 28447479
[TBL] [Abstract][Full Text] [Related]
20. Constitutive lymphocyte transmigration across the basal lamina of high endothelial venules is regulated by the autotaxin/lysophosphatidic acid axis.
Bai Z; Cai L; Umemoto E; Takeda A; Tohya K; Komai Y; Veeraveedu PT; Hata E; Sugiura Y; Kubo A; Suematsu M; Hayasaka H; Okudaira S; Aoki J; Tanaka T; Albers HM; Ovaa H; Miyasaka M
J Immunol; 2013 Mar; 190(5):2036-48. PubMed ID: 23365076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
